FMC — FMC Corporation

FMC Corporation Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Sales: $762 million, exceeding the guidance midpoint by $12 million but down 4% year-over-year. On a like-for-like basis (excluding India), sales increased by 1%.
• Adjusted EBITDA: $72 million, surpassing the high end of guidance by $17 million.
• Adjusted Loss Per Share: $0.23, better than the guidance midpoint by $0.15.
• Free Cash Flow: Negative $628 million, a decline from the previous year, attributed to lower EBITDA.
• Debt: Gross debt increased to approximately $4.5 billion; net debt rose to about $4.1 billion, reflecting seasonal working capital build.

2. Strategic Updates and Business Highlights

• Operational Priorities: FMC is focused on debt reduction (targeting $1 billion in 2026), optimizing manufacturing costs, managing the post-patent transition for Rynaxypyr, and supporting sales growth of new active ingredients.
• New Products: Sales of new active ingredients doubled year-over-year in Q1. Regulatory approval for Isoflex active in the EU was achieved, with launches expected in 2027.
• Cost Structure Optimization: FMC is transitioning production to lower-cost plants in Asia, aiming for completion by Q1 2027.

3. Forward Guidance and Outlook

• Q2 Revenue Guidance: Expected between $850 million and $900 million, reflecting a 17% decline at the midpoint due to lower sales to diamide partners and the removal of India.
• Full Year 2026 Guidance: Sales projected at $3.6 billion to $3.8 billion (5% decline at midpoint), EBITDA expected between $670 million and $730 million (17% decline), and adjusted EPS between $1.63 and $1.89 (41% decline).
• Second Half Outlook: Anticipated sales and EBITDA to be consistent with last year's second half, driven by volume growth from new active ingredients.

4. Bad News, Challenges, or Points of Concern

• Competitive Pressures: The market is increasingly impacted by low-cost generic competitors, particularly in Latin America and Asia.
• Declining Metrics: Sales to diamide partners are expected to decline significantly, contributing to overall revenue drops.
• Cost Pressures: Higher energy, transportation, and petrochemical costs are anticipated, with uncertainty regarding the impact of tariffs and the ongoing conflict in Iran.
• Market Conditions: Cautious purchasing behavior from customers due to stressed liquidity and lower grower margins.

5. Notable Q&A Insights

• Challenges in H2: CEO Pierre Brondeau highlighted that the biggest challenges for the second half include maintaining order volumes, particularly in Brazil, and managing pricing strategies amidst increased competition.
• Rynaxypyr Strategy: There are early signs of gaining market share from other insecticides, particularly in North America, but the real test will be in Q3 and Q4 as generics become more active.
• Licensing Opportunities: FMC is in advanced discussions for licensing new active ingredients, which may include upfront payments.
• Tariff Refunds: There is potential for tariff refunds, but the process is uncertain and dependent on ongoing legal proceedings.

This summary encapsulates the key points from FMC's Q1 2026 earnings call, reflecting both the company's progress and the challenges it faces in the current market environment.